• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Newsmakers: Darren Shirley

    Are You Prepared for the 2023 DSCSA Deadline?

    Rethinking the Changing Role of the CRO

    23rd Annual Salary Survey

    Pharma 4.0 and the Modernizing Power of Digital Technology Transfer
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Ixaka & Minaris Sign Tech Transfer & GMP Manufacturing Agreement for Cell Therapy Candidate

    Pfizer, BioNTech Adapt COVID Vax Against Omicron

    CoreRx Expands Capabilities

    Pierre Fabre and Lonza Enter Manufacturing Agreement

    MasterControl and Elemental Machines Form Biomanufacturing Partnership
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    CoreRx Expands Capabilities

    Pierre Fabre and Lonza Enter Manufacturing Agreement

    Qosina Strengthens Aseptic Capabilities

    MilliporeSigma Opens $65M CDMO Facility for Cancer Therapies

    Antheia Receives $40 million in Venture Debt Financing
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Tubular Glass Primary Packaging for Pharmaceutical, Biotech and Diagnostic Containment

    How to Improve the Cold Chain System in Remote Locations

    Sentry Biopharma Services: Protecting Pharmaceutical Integrity

    Yourway to Build New Flagship European Depot

    Newsmakers: Darren Shirley
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Ixaka & Minaris Sign Tech Transfer & GMP Manufacturing Agreement for Cell Therapy Candidate

    MasterControl and Elemental Machines Form Biomanufacturing Partnership

    Charles River and Ziphius Vaccines to Manufacture saRNA-based Vaccine

    Cullinan Oncology, Taiho to Develop & Commercialize CLN-081/TAS6417 in the U.S.

    BioNTech Breaks Ground on First mRNA Vax Mfg. Facility in Africa
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Should Remote Pharma GMP Audits End After COVID?

    Why is Big Pharma Increasingly Adopting 505(b)(2)?

    Sentry Biopharma Services: Protecting Pharmaceutical Integrity

    Selkirk Pharma Appoints New Head of Quality

    Be Safer by Doing Less: The Future of Zero Touch AE Case Processing
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Quotient Sciences

    Biosynth Carbosynth

    CMC Pharmaceuticals

    Aphena Pharma Solutions

    Kyongbo Pharmaceutical
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Quotient Sciences

    Biosynth Carbosynth

    CMC Pharmaceuticals

    Aphena Pharma Solutions

    Kyongbo Pharmaceutical
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    Economics of In-House Buffer Preparation

    Evaluating the cost effectiveness of keeping basic ops in-house

    Related CONTENT
    • Bora Pharmaceuticals
    • Dr. Reddy’s Expands Biomanufacturing Capabilities
    • Current Trends in Analytical Testing
    • CMOs & Biosimilars Mfg. in the U.S.
    • CMOs Hiring Constraints: Cell Therapy Manufacturing Expecting Future Challenges
    Eric S. Langer, BioPlan Associates09.08.16
    Buffer preparation, like culture media preparation, is a task classically performed in-house by bioprocessing facilities. Until recently, preparation of these working fluids has generally been viewed as a “core” operation to be kept in-house and not outsourced.  However, some biomanufacturers have been questioning and evaluating the cost effectiveness of keeping relatively basic operations like buffer prep in-house, when suppliers are beginning to offer these as outsourced materials. BioPlan Associates conducted a follow-on study to our analysis in 2014 to assess the cost-effectiveness of buffer preparation done in-house. These data can be used to evaluate outsourcing options.

    Increasingly, these classically core powder hydration/prep operations are candidates for outsourcing as biomanufacturers seek to do more with fewer staff at lower costs. Bioprocessing facilities have generally taken an in-house platform approach to buffer—and media—preparation, using common equipment. 

    But there are total facility costs associated with buffer preparation that differ between facility types. We wanted to assess how these costs vary based on facility size and bioprocessing scales. And how costs of buffer prep using stainless steel compare to use of single-use equipment or hybrid. 

    In our earlier study of bioprocessing fluids outsourcing we found that nearly half of the respondents (47%), indicated that large-scale media and buffer prep outsourcing was an option they would actively consider. Thus, even core bioprocessing tasks, such as buffer prep, are becoming candidates for outsourcing. In some cases, purchase and delivery of buffer—and culture media—fluid prepared remotely by buffer fluid vendors or hired CMOs may be preferred and potentially more cost-effective than in-house preparation. Not unexpectedly, this tends to more be the case for smaller facilities, facilities doing intermittent bioprocessing. While in-house prep generally remains the pattern at larger commercial scales. Shipping of fluids can very often be the main cost in purchase of pre-prepared bioprocessing fluids. 

    But with buffer prep as with other operations, there are other factors involved beside materials and other direct/variable costs. These are captured in the model, such as overhead; allocated facility support services like administrative, and validation; costs of depreciation, etc. In addition, other intangible factors can make outsourcing more attractive. These include aspects like:
    • Potentially higher quality materials delivered from suppliers;
    • Ability to re-allocate production space from buffer prep to bioreactor capacity (utilization of classified space);
    • Speed of development (often more important than costs);
    • Regulatory compliance and documentation (absolute requirements);
    • Rapid process turnover;
    • Efficient use of staff;
    • Demands for flexible and lean operations;
    • Inventory management and warehousing;
    • Space availability;
    • Need for training; and
    • Demands for bioprocessing sterility.
    The recent study did not include consideration of these aspects, rather solely concerned itself with total in-house buffer prep costs.

    Study methodology
    To answer these questions, we developed a buffer costs preparation model based on prior research and on financial and cost inputs from industry segment experts. From this we developed a comparative buffer prep costs model (spreadsheet). We then performed a series of in-depth interviews collecting information from bioprocessing professionals that had calculated their in-house costs for buffer preparation. From this we developed a buffer prep costs model. We interviewed 10 industry staff for this project, to update cost data from 32 relevant industry end-users performed in 2014.1

    For this recent buffer costs modeling effort, expert bioprocessing professionals having calculated their in-house costs for buffer preparation, were interviewed to collect their costs estimation data. Rather than collecting only bottom line cost conclusions, interviews concentrated on trying to understand and consistently record individual cost component. Although few interviewees used the same methodologies for their internal cost accounting, we were able to estimate cost-per-liter data to help with consistency.

    Table I presents the types of buffer-related cost categories discussed in interviews. These headings may be useful as a checklist to develop buffers-related cost estimate data. As noted, a potential weakness with interviewee-collected cost estimate data is that there are no industry-accepted methods for determining and allocating bioprocessing task-related cost parameter. In many cases, obtaining cost data involved estimating each cost item jointly with interviewees. For each component cost (Table I), its current average per year cost was requested or developed. For example, “Capital Facility Expenses (Buffer Prep Building, excluding Equip/HVAC),” involved total building construction cost and determining ongoing annual financial burden, e.g., by amortizing total building costs over time at 4%, and then prorating this by the estimated percentage of facility space allotted to buffers. Buffer prep-related construction costs also vary greatly, depending on the facility size and bioprocessing scale. 

    Study results
    Figure 1 shows results of averaging estimated total in-house buffer-prep costs for different size facilities. The overall average cost for in-house buffer preparation was $19.72. Note, the costs for buffer prep do not include costs related to buffer R&D, process design/development, etc.; and only buffer prep from source powders, not from fluid concentrates, was considered. The costs of in-house automated buffer prep dilution from outsourced purchased concentrates, a growing trend but still mostly used only at commercial manufacturing scales, were not considered in this study.

    As expected and shown in Figure 1, costs/L of buffers tend to decrease as facility size and bioprocessing scales increase. Estimated average costs ranged from nearly $30/L for smaller facilities, those producing <100,000 L of buffers/year, to about $11 at largest scales, >1,000,000 L/year. Figure 1 also shows, as fully expected, the total facility costs generally increasing as facility size and bioprocessing scale go up, with facilities at <100,000 L/year having annual average buffer prep costs of $2.6 million, while those at largest scales, >1,000,000 L/year, have costs averaging in multiple $10s of millions. Note, some excess buffer manufacturing capacity is generally prudent, if not critical, for bioprocessing facilities to have, but with any such unused capacity adds to operational costs. Some excess capacity is needed, because the opportunity, loss of speed, and other costs of not having some flexible excess capacity when needed, such as need to supply product launches, deal with any buffer-related bottlenecks, avoid shortages, etc. can be devastating to a product and company.

    Facility type findings
    Average annual total buffer prep costs by type of facility, whether stainless steel, single-use or hybrid systems—used for buffer prep—also varied in the study. Operating at very large scales using stainless steel systems generally provide the lowest in-house buffer prep per liter costs, with average cost for stainless steel facilities at $11.92/L, while single-use facilities average $21.80. Note that the sample size for these facilities is insufficient to address issues of scale. However, because single-use scales are typically significantly smaller, these data suggest scaling factors should also be considered. The overall average annual average total costs for buffer prep for all facilities surveyed was $8.5 million. Overall, total average costs for in-house buffer prep were higher for stainless steel facilities, $13.2 million/year, but with these facilities tending to include larger commercial manufacturing regulatory compliance and documentation, operating at much larger scale than the others. The overall average cost for single-use facilities was $5.5 million.

    The average facility fixed costs by facility size were also evaluated. Average for all facilities’ fixed costs were $4.47/L or about 22.6% of the average total cost. There is a general trend for lower fixed costs/L at larger scales, as expected. Average per liter costs are $6.77 at small scales (<100,000 L/year); but $3.08 at largest, >1,000,000 L/year scale. 

    Average annual in-house buffer prep fixed costs by facility type included fixed cost/liter for stainless steel facilities at $3.55/L; and $3.87 for single-use. 

    Average annual total variable costs by facility size generally trended lower as facility size and bioprocessing scales increase. The overall average annual variable costs were $10.67/L. Small facilities (<100,000 L/year) had average costs of $14.86/L; those at the largest facilities, >1,000,000 L/year had average costs of $4.88.
    Variable costs by facility type, not unexpectedly, showed single-use facilities as having higher costs. Overall average annual variable buffer prep costs was $10.67/L, with single-use at $12.37/L and stainless steel at $6.92/L. Stainless steel costs are expected to be lowest, with single-use system equipment needing to be purchased new for each bioprocessing run or campaign.

    There is a general trend for lower labor costs/L, i.e., higher staff productivity, as facility size and (bioprocessing scales increase. Average cost/L vary over a range about 100%, from the lowest $3.17/L at largest scales (>1,000,000 L/year) to highest at $7.54/L at small scale (<100,000 L/year).

    Conclusions
    The difference and trends with total in-house average annual buffer prep from powder costs were generally as expected. Costs per liter were lower and productivity was higher for larger and stainless steel facilities, with being larger facilities generally stainless steel—and vice versa. 

    Although the costs for outsourcing of buffer fluids preparation are generally significantly higher than for in-house preparation as expected, the intangible value of outsourced buffers may outweigh a simple cost calculation. Further, though outsourced fluids may reduce some costs, certain costs remain, including storage, staff time, regulatory filings, on-site filtration, management overhead, QA/QC lab, and other costs included in the in-house total cost calculations may also apply to externally purchased buffers. 

    References
    1. Langer, E.S., “Outsourcing Media and Buffer Prep,” Contract Pharma, Sept. 8, 2014.


    Eric S. Langer
    BioPlan Associates

    Eric S. Langer is president and managing partner at BioPlan Associates, Inc., a biotechnology and life sciences marketing research and publishing firm established in Rockville, MD in 1989. He is editor of numerous studies, including “Biopharmaceutical Technology in China,” “Advances in Large-scale Biopharmaceutical Manufacturing”, and many other industry reports.  elanger@bioplanassociates.com  301-921-5979.  www.bioplanassociates.com
    Related Searches
    • Biologics, Proteins, Vaccines
    Suggested For You
    Bora Pharmaceuticals Bora Pharmaceuticals
    Dr. Reddy’s Expands Biomanufacturing Capabilities Dr. Reddy’s Expands Biomanufacturing Capabilities
    Current Trends in Analytical Testing Current Trends in Analytical Testing
    CMOs & Biosimilars Mfg. in the U.S. CMOs & Biosimilars Mfg. in the U.S.
    CMOs Hiring Constraints:  Cell Therapy Manufacturing Expecting Future Challenges CMOs Hiring Constraints: Cell Therapy Manufacturing Expecting Future Challenges
    Year-End Trends in Biopharma Contract Manufacturing Year-End Trends in Biopharma Contract Manufacturing
    Technology Trends: Disposable Vs. Stainless Steel Technology Trends: Disposable Vs. Stainless Steel
    Contract Manufacturing Budget Trends Contract Manufacturing Budget Trends
    China Vaults to the Top of U.S. Biomanufacturers’ Off-Shoring Prospects China Vaults to the Top of U.S. Biomanufacturers’ Off-Shoring Prospects
    Taking Stock of Biopharma’s Outsourcing Markets Taking Stock of Biopharma’s Outsourcing Markets
    Globalization Hits Biopharma Contract Manufacturing Globalization Hits Biopharma Contract Manufacturing
    CMOs Are Willing to Pay for More Innovation CMOs Are Willing to Pay for More Innovation
    Getting to Yes Getting to Yes
    Banging the CMO Drum
Banging the CMO Drum
    CMOs Facing Significant Capacity Constraints CMOs Facing Significant Capacity Constraints

    Related Content

    • Bora Pharmaceuticals

      Bora Pharmaceuticals

      ...
      Lonnie Barish, VP, Business Development 03.09.22

    • Bio News | Biologics, Proteins, Vaccines | Industry News
      Dr. Reddy’s Expands Biomanufacturing Capabilities

      Dr. Reddy’s Expands Biomanufacturing Capabilities

      Becomes first Indian company to install FlexFactory single-use platform
      05.19.17

    • Bioanalytical Services
      Current Trends in Analytical Testing

      Current Trends in Analytical Testing

      Improved analytical methods continues to be a current need for nearly every aspect of biopharma manufacturing
      Eric S. Langer, BioPlan Associates 05.09.17


    • Biosimilars
      CMOs & Biosimilars Mfg. in the U.S.

      CMOs & Biosimilars Mfg. in the U.S.

      Biosimilars are moving from novel opportunity to mainstream product
      Eric S. Langer and Ronald A. Rader, BioPlan Associates 04.20.17

    • Biologics, Proteins, Vaccines
      CMOs Hiring Constraints:  Cell Therapy Manufacturing Expecting Future Challenges

      CMOs Hiring Constraints: Cell Therapy Manufacturing Expecting Future Challenges

      Technically trained staff needed to run complex manufacturing platforms, automation
      Eric S. Langer, BioPlan Associates 03.07.17

      Loading, Please Wait..
      Trending
      • Pierre Fabre And Lonza Enter Manufacturing Agreement
      • 17th Annual Contracting & Outsourcing Conference Photos
      • Machine Learning-based Predictive Modeling: Notable Uses In Clinical Trials
      • LabVantage Solutions Adds Mixed Reality Technology to Its Advanced LIMS Platform
      • MilliporeSigma Opens $65M CDMO Facility For Cancer Therapies
      Breaking News
      • Ixaka & Minaris Sign Tech Transfer & GMP Manufacturing Agreement for Cell Therapy Candidate
      • Pfizer, BioNTech Adapt COVID Vax Against Omicron
      • CoreRx Expands Capabilities
      • Qosina Strengthens Aseptic Capabilities
      • Charles River and Ziphius Vaccines to Manufacture saRNA-based Vaccine
      View Breaking News >
      CURRENT ISSUE

      June 2022

      • Newsmakers: Darren Shirley
      • Are You Prepared for the 2023 DSCSA Deadline?
      • Rethinking the Changing Role of the CRO
      • 23rd Annual Salary Survey
      • Pharma 4.0 and the Modernizing Power of Digital Technology Transfer
      • CEO Spotlight: David Chang
      • Changes are on the Horizon for Single-use Systems in Pharmaceutical Manufacturing
      • CRO Industry Market Report

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Japanese Mushroom Extract Appears Helpful in HPV Infections
      Fi & Hi Europe Returns with Over 20,000 Global Attendees Expected
      United Plant Savers Launches First Film Festival
      Coatings World

      Latest Breaking News From Coatings World

      H.M. Royal Becomes Exclusive OCSiAl Distributor
      American Colors to Expand Sandusky, Ohio Facility
      Vaughn O’Dea Named Director of Epoxytec
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      Accelmed Partners II, Lauxera Capital Partners Invest in Veranex
      Agnes Lee Named SVP of Investor Relations, Strategic Planning at Inogen
      Dr. Brandee Pappalardo Joins Fresenius Kabi as Chief Medical Officer
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Ixaka & Minaris Sign Tech Transfer & GMP Manufacturing Agreement for Cell Therapy Candidate
      Pfizer, BioNTech Adapt COVID Vax Against Omicron
      CoreRx Expands Capabilities
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      Top 5 Beauty Tech Trends at Perfect Corp.'s Global Forum
      John Frieda Supports the LGBTQIA+ Community
      Athena Club Launches in Canada
      Happi

      Latest Breaking News From Happi

      Past Henkel Exec Christian Chopra Named President of Scotch Porter
      Color Street Celebrates Foster, Adoption Awareness with Limited-Edition Print
      CIR Panel Conducts 161st Meeting Regarding Safety Assessments for Cosmetic Ingredients
      Ink World

      Latest Breaking News From Ink World

      Dr. Tammo Boinowitz to Join Management Board of ALTANA AG
      Flint Offset Packaging Solutions Announces Price Increases for Sheetfed Inks
      Weekly Recap: INX’s VC Fund, Screen Industry and Ball Top This Week’s News
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      Harveer Sahni recognized with Global Achievement Award
      Color-Logic partners with Taktiful 
      ALTANA announces Management Board change
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Fibertex Personal Care Awarded EcoVadis Awards for Sustainability
      Yanpai Orders Batt Forming Equipment for Needlepunch Line
      Weekly Recap: SWM and Neenah Introduce Mativ Inc., Avgol honored for Biotransformation Technology & More
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      Researchers Discover Novel Patching Material for Bone Defects
      Boston Centerless Opens Second Manufacturing Plant in Indiana
      Researchers Develop Patient-Specific 3D-Printed Smart Metamaterial Implants
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Identiv-Powered CVS Spoken Rx Wins NFC Forum 2022 Innovation Award
      LG Display Announces Winners of This Year’s OLEDs GO! Competition
      Weekly Recap: eMagin, Applied Materials, and Schott Top This Week’s Stories

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login